keyword
MENU ▼
Read by QxMD icon Read
search

Gastroesophageal junction cancer

keyword
https://www.readbyqxmd.com/read/29234525/invasive-candida-infection-after-upper-gastrointestinal-tract-surgery-for-gastric-cancer
#1
Evgeni Brotfain, Gilbert Sebbag, Michael Friger, Boris Kirshtein, Abraham Borer, Leonid Koyfman, Dmitry Frank, Yoav Bichovsky, Jochanan G Peiser, Moti Klein
Upper gastrointestinal tract (GIT) surgical procedures are more likely to cause nosocomial Candida peritonitis than lower GIT procedures and they thus constitute an independent risk factor for mortality. Because of the severity of postsurgical fungal infections complications, intensivists and surgeons need to be extremely aware of their clinical importance in critically ill postsurgical intensive care unit (ICU) patients. We analyzed the clinical and microbiological data of 149 oncologic patients who were hospitalized in the ICU at Soroka Medical Center between January 2010 and January 2015 after undergoing upper GIT surgery for gastric cancer...
2017: International Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29228632/survival-benefit-of-anti-angiogenic-agents-in-patients-with-previously-treated-advanced-gastric-or-gastroesophageal-junction-cancer-a-meta-analysis
#2
Jung Han Kim, Hyeong Su Kim, Bum Jun Kim, Hyun Joo Jang
There is a debate as to whether anti-angiogenic molecular agents can produce survival benefits in patients with previously treated advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC). We performed this meta-analysis of randomized trials to evaluate the survival outcomes of an anti-angiogenic agent versus placebo in the salvage treatment of advanced GC or GEJC. Electronic databases were searched for eligible studies. From the four studies, 910 patients with previously treated advanced GC or GEJC were included in the meta-analysis...
November 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/29215372/efficacy-and-safety-of-apatinib-as-second-line-therapy-for-advanced-gastric-cancer-a-single-center-observational-study
#3
Yong Zhang, Miaomiao Gou, Chun Han, Juan Li, Lijie Wang, Qian Qiao, Yi Hu, Li Bai, Zhefeng Liu
Apatinib has been proven to be effective and safe among patients in the third-line treatment of advanced gastric cancer in phase II and III trials. We aimed to evaluate its efficacy and safety in second-line practice, and to explore the factors associated with efficacy. Between April 2015 and May 2017, a total of 23 patients with advanced gastric adenocarcinoma or adenocarcinoma of gastroesophageal junction were enrolled and followed up retrospectively after failing the first line of systemic therapy. The median progression-free survival was 4...
December 5, 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29182797/palliative-chemotherapy-and-targeted-therapies-for-esophageal-and-gastroesophageal-junction-cancer
#4
REVIEW
Vincent T Janmaat, Ewout W Steyerberg, Ate van der Gaast, Ron Hj Mathijssen, Marco J Bruno, Maikel P Peppelenbosch, Ernst J Kuipers, Manon Cw Spaander
BACKGROUND: Almost half of people with esophageal or gastroesophageal junction cancer have metastatic disease at the time of diagnosis. Chemotherapy and targeted therapies are increasingly used with a palliative intent to control tumor growth, improve quality of life, and prolong survival. To date, and with the exception of ramucirumab, evidence for the efficacy of palliative treatments for esophageal and gastroesophageal cancer is lacking. OBJECTIVES: To assess the effects of cytostatic or targeted therapy for treating esophageal or gastroesophageal junction cancer with palliative intent...
November 28, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29154240/polish-consensus-on-treatment-of-gastric-cancer-update-2017
#5
Jan Kulig, Grzegorz Wallner, Michał Drews, Mariusz Frączek, Arkadiusz Jeziorski, Wojciech Kielan, Piotr Kołodziejczyk, Anna Nasierowska-Guttmejer, Teresa Starzyńska, Krzysztof Zinkiewicz, Marek Wojtukiewicz, W Tomasz Skoczylas, Piotr Richter, Marek Krawczyk
The "Polish Research on Gastric Cancer" project has been continued since 1986. The main aim of this project, which is a multicenter and interdisciplinary research, is enhancing the treatment results of gastric cancer patients by developing and promoting the use of optimal methods for diagnosis and treatment, both surgical as well as combined. One of the more important achievements of the project is the development and publication of a document named "Polish Consensus on Treatment of Patients with Gastric Cancer", whose first version was published in 1998...
October 31, 2017: Polski Przeglad Chirurgiczny
https://www.readbyqxmd.com/read/29136993/reply-to-pretreatment-neutrophil-to-lymphocyte-ratio-independently-predicts-disease-specific-survival-in-patients-with-resectable-gastroesophageal-junction-and-gastric-cancer
#6
https://www.readbyqxmd.com/read/29136992/pretreatment-neutrophil-to-lymphocyte-ratio-independently-predicts-disease-specific-survival-in-patients-with-resectable-gastroesophageal-junction-and-gastric-cancer
#7
Masayuki Urabe, Hiroharu Yamashita, Yasuyuki Seto
No abstract text is available yet for this article.
December 2017: Annals of Surgery
https://www.readbyqxmd.com/read/29130643/pilot-study-on-preventing-anastomotic-leakage-in-stapled-gastroesophageal-anastomosis
#8
Shijie Zhang, Weiming Huang, Xiangzheng Liu, Jian Li
BACKGROUND: This study explored how to improve the surgical technique to reduce or avoid anastomotic leakage. METHODS: From January 2012 to December 2016, 101 consecutive patients with cancer of the esophagus or gastroesophageal junction underwent stapled gastroesophageal anastomosis. The procedure included creating a tube-type stomach, fixing an inserted anvil, inspecting mucosa-to-mucosa alignment in the lumen under direct vision after firing the stapler, and, if found, manually repairing a rupture of the mucous membrane of the anastomosis...
November 11, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/29129092/adenocarcinoma-of-the-esophagus-controversies-and-consensus
#9
David H Ilson
Esophageal cancer, the sixth most common cause of cancer globally, is characterized by the development of early systemic metastatic disease. Adenocarcinoma of the esophagus and gastroesophageal junction (GEJ) is more common in the West. Preoperative chemotherapy or chemoradiotherapy is employed for locally advanced disease with contemporary studies suggesting higher rates of curative resection and reduced rates of local recurrence with the combination of chemotherapy and radiation therapy given prior to surgery...
October 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/29098306/-differentiated-surgical-approach-for-adenocarcinoma-of-the-gastroesophageal-junction
#10
REVIEW
W Schröder, R Lambertz, R van Hillegesberger, C Bruns
For adenocarcinoma of the gastroesophageal junction (GEJ) the classification of Siewert with its three subtypes is well established as a practical approach to surgical treatment. Transthoracic esophagectomy with gastric tube formation is generally accepted as the surgical standard for adenocarcinoma of the distal esophagus (GEJ type I). Intrathoracic esophagogastrostomy has become the most frequently used anastomotic technique (Ivor Lewis esophagectomy). Both the abdominal and thoracic part can be safely performed with a minimally invasive access...
November 2, 2017: Der Chirurg; Zeitschrift Für Alle Gebiete der Operativen Medizen
https://www.readbyqxmd.com/read/29089808/shifting-practice-in-definitive-chemoradiation-for-localized-esophageal-cancer
#11
X M Qu, J J Biagi, W M Hopman, A Mahmud
BACKGROUND: The efficacy of carboplatin-paclitaxel in the trimodality setting was demonstrated in the cross trial. Because of better tolerance, that regimen has been adopted as an alternative for patients receiving definitive chemoradiation (dcrt). The purpose of our study was to compare outcomes in patients with localized esophageal and gastroesophageal junction (gej) cancer who received dcrt using either platinum-5-fluorouracil (5fu) or carboplatin-paclitaxel. METHODS: Medical records and outcomes for all patients diagnosed with localized carcinoma of the esophagus and gej at our centre between 2008 and 2015 were reviewed...
October 2017: Current Oncology
https://www.readbyqxmd.com/read/29071366/perioperative-chemotherapy-vs-neoadjuvant-chemoradiation-in%C3%A2-gastroesophageal-junction-adenocarcinoma-a-population-based-evaluation-of-the-munich-cancer-registry
#12
Stefan Münch, Daniel Habermehl, Ayman Agha, Claus Belka, Stephanie E Combs, Renate Eckel, Helmut Friess, Alexander Gerbes, Natascha C Nüssler, Wolfgang Schepp, Roland M Schmid, Wolfgang Schmitt, Gabriele Schubert-Fritschle, Bernhard Weber, Jens Werner, Jutta Engel
BACKGROUND: To date, it remains unclear whether locally advanced adenocarcinoma of the gastroesophageal junction (AEG) should be treated with neoadjuvant chemoradiation (nCRT), analogous to esophageal cancer, or with perioperative chemotherapy (pCT), analogous to gastric cancer. The purpose of this study was to analyze the data of the Munich Cancer Registry (MCR) and to compare pCT and nCRT in AEG patients. PATIENTS AND METHODS: A total of 2,992 AEG patients, treated between 1998 and 2014, were included in the study...
October 25, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29038432/efficacy-and-safety-for-apatinib-treatment-in-advanced-gastric-cancer-a-real-world-study
#13
Yong Zhang, Chun Han, Juan Li, Li Zhang, Lijie Wang, Sisi Ye, Yi Hu, Li Bai
Apatinib has been proved to be effective and safe among patients in gastric cancer in Phase II and III Trials. We aimed to evaluate its efficacy and safety in real world practice, and to explore factors associated with efficacy. Between January 2015 and February 2017, totally 36 patients with advanced gastric adenocarcinoma or adenocarcinoma of gastroesophageal junction (GEJ) were enrolled and followed up retrospectively after failing at least two lines of systemic therapy. The mPFS was 2.65 months (95%CI 1...
October 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29019570/thoraco-laparoscopic-esophagectomy-thoracic-stage-in-prone-position
#14
Carlos Bernardo Cola, Flávio Duarte Sabino, Carlos Eduardo Pinto, Maria Ribeiro Morard, Pedro Portari, Tereza Guedes
OBJECTIVE: to analyze the National Cancer Institute Abdominopelvic Division (INCA / MS/HC I) initial experience with thoraco-laparoscopic esophagectomy with thoracic stage in prone position. METHODS: we studied 19 consecutive thoraco-laparoscopic esophagectomies from may 2012 to august 2014, including ten patients with squamous cells carcinoma (five of the middle third and five of the lower third) and nine cases of gastroesophageal junction adenocarcinoma (six Siewert I and three Siewert II)...
September 2017: Revista do Colégio Brasileiro de Cirurgiões
https://www.readbyqxmd.com/read/28977971/meta-analysis-of-sirt1-expression-as-a-prognostic-marker-for-overall-survival-in-gastrointestinal-cancer
#15
Shuangjie Wu, Jinghui Jiang, Jun Liu, Xinhai Wang, Yu Gan, Yifan Tang
Sirtuin 1 (SIRT1), a well-characterized NAD(+)-dependent histone deacetylase, is generally up-regulated in gastrointestinal cancers. However, the prognostic value of SIRT1 in gastrointestinal cancer remains inconclusive. Therefore, we report a meta-analysis of the association of SIRT1 expression with overall survival (OS) in gastrointestinal cancer. PubMed was systematically searched for studies evaluating the expression of SIRT1 and OS in patients with gastrointestinal cancer. Fifteen studies (six evaluating colorectal cancer, three evaluating hepatocellular carcinoma, three evaluating gastric cancer, and one each evaluating pancreatic cancer, esophageal squamous cell carcinoma, and gastroesophageal junction cancer) with 3,024 patients were finally included...
September 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28976791/adjuvant-chemoradiotherapy-with-epirubicin-cisplatin-and-fluorouracil-compared-with-adjuvant-chemoradiotherapy-with-fluorouracil-and-leucovorin-after-curative-resection-of-gastric-cancer-results-from-calgb-80101-alliance
#16
RANDOMIZED CONTROLLED TRIAL
Charles S Fuchs, Donna Niedzwiecki, Harvey J Mamon, Joel E Tepper, Xing Ye, Richard S Swanson, Peter C Enzinger, Daniel G Haller, Tomislav Dragovich, Steven R Alberts, Georg A Bjarnason, Christopher G Willett, Leonard L Gunderson, Richard M Goldberg, Alan P Venook, David Ilson, Eileen O'Reilly, Kristen Ciombor, David J Berg, Jeffrey Meyerhardt, Robert J Mayer
Purpose After curative resection of gastric or gastroesophageal junction adenocarcinoma, Intergroup Trial 0116 (Phase III trial of postoperative adjuvant radiochemotherapy for high risk gastric and gastroesophageal junction adenocarcinoma: Demonstrated superior survival for patients who received postoperative chemoradiotherapy with bolus fluorouracil (FU) and leucovorin (LV) compared with surgery alone. CALGB 80101 (Alliance; Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma) assessed whether a postoperative chemoradiotherapy regimen that replaced FU plus LV with a potentially more active systemic therapy could further improve overall survival...
November 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28973403/a-phase-1-1b-tolerability-study-of-rilotumumab-alone-or-in-combination-with-cisplatin-and-capecitabine-in-japanese-patients-with-gastric-cancer
#17
Toshihiko Doi, Kensei Yamaguchi, Yoshito Komatsu, Kei Muro, Tomohiro Nishina, Takako Eguchi Nakajima, Rui Tang, Hui Yang, Yilong Zhang, A Scott Jung, Agnes Ang, Hirofumi Yasui
Objective: To evaluate the safety (including adverse events and dose-limiting toxicities [DLTs]), tolerability, pharmacokinetics and antitumor activity of the investigational MET inhibitor rilotumumab alone in patients with advanced solid tumors (Part 1) or in combination with cisplatin plus capecitabine (CX) in patients with MET-positive advanced gastric or gastroesophageal junction cancer (Part 2). Methods: Adult patients received 10 or 20 mg/kg intravenous (IV) rilotumumab every 2 weeks (Part 1) or 15 mg/kg IV rilotumumab every 3 weeks plus 80 mg/m2 cisplatin on Day 1 and 1000 mg/m2 capecitabine twice daily on Days 1-14 of every 21-day cycle (Part 2)...
August 22, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28967981/pharmacokinetic-drug-interactions-of-apatinib-with-rifampin-and-itraconazole
#18
Xiaoyun Liu, Yifan Zhang, Qian Chen, Yan Zhan, Quanren Wang, Chaoying Hu, Chen Yu, Zitao Guo, Xiaoyan Chen, Dafang Zhong
Apatinib is a small-molecule tyrosine kinase inhibitor that has been approved for the treatment of patients with advanced-stage gastric cancer or gastroesophageal junction cancer who have progressed or recurred after at least 2 kinds of systemic chemotherapy. In vitro data indicate that cytochrome P450 (CYP) 3A4 is the primary CYP isoenzyme involved in the metabolism of apatinib. Pharmacokinetic drug-drug interactions of apatinib and (1) a CYP3A4 inducer (rifampin) or (2) a CYP3A inhibitor (itraconazole) were clinically evaluated in healthy volunteers...
October 2, 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28960444/age-does-not-influence-efficacy-of-ramucirumab-in-advanced-gastric-cancer-subgroup-analyses-of-regard-and-rainbow
#19
Kei Muro, Jae Yong Cho, Gyorgy Bodoky, Chanchal Goswami, Yee Chao, Lucas V Dos Santos, Yasuhiro Shimada, Eldar Topuzov, Eric Van Cutsem, Josep Tabernero, John Zalcberg, Ian Chau, Stefano Cascinu, Rebecca Cheng, Yanzhi Hsu, Michael Emig, Mauro Orlando, Charles Fuchs
BACKGROUND AND AIM: REGARD and RAINBOW were global, phase 3, randomized, double-blind trials of second-line ramucirumab for metastatic gastric or gastroesophageal junction adenocarcinoma. We describe exploratory subgroup analyses to assess the efficacy and safety of ramucirumab in REGARD and RAINBOW in young (≤45 and <65 years) and elderly (≥65, ≥70 and ≥75 years) patients. METHODS: Patients were randomized 2:1 to receive ramucirumab plus best supportive care or placebo plus best supportive care (REGARD) or 1:1 to ramucirumab plus paclitaxel or placebo plus paclitaxel (RAINBOW)...
September 29, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28953685/gastric-cancer-in-a-situs-inversus-totalis-patient-with-multiple-intestinal-and-vessel-variations-related-to-gastrectomy-surgery-a-case-report-and-literature-review
#20
Yinghao Cao, Jiang Li, Liming Shen, Jiliang Wang, Zefeng Xia, KaiXiong Tao, Guobin Wang, Kailin Cai
RATIONALE: Situs inversus totalis (SIT) is a rare congenital anomaly characterized by complete inversion of the abdominal and thoracic organs, and often involves multiple genetic mutations. The most suitable surgical technique for patients with multiple vessel and organ variations as well as SIT remains unclear. Furthermore, there has been insufficient clinical evidence that demonstrates which surgical techniques achieve the best outcomes. Finally, the standard of care has not yet been determined...
September 2017: Medicine (Baltimore)
keyword
keyword
50345
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"